Co-Diagnostics, Inc. CODX 深 滬
等待開盤 06-25 09:30:00 美东时间
3.57
+0.340
+10.53%
華盛通- 最 高3.75
- 今 開3.20
- 成交量 98.93万股
- 最 低 3.19
- 昨 收 3.23
- 總市值 1874.22万
- 52周最高 13.54
- 市盈率 靜 --
- 換手率 18.84%
- 52周最低 1.26
- 委 比 -48.19%
- 總股本 524.99万
- 歷史最高 13.54
- 量 比 2.53
- 振 幅 17.34%
- 歷史最低 1.26
- 每 手 1
- 風險率 2.01%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Co-Diagnostics Announces Delegation Visit From CoMira Diagnostics At Co. Headquarters In Salt Lake City; Unveils Future Automated Production Line At Technology, Innovation Event
Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that a delegation from CoMira Diagnostics ("CoMira"), the Company's joint venture with partners in the Ki...
06-18 21:18
Co-Diagnostics Enters Into Exclusive Distribution Agreement With Partner In Mexico For Co-Dx PCR Point-Of-Care Platform
Longstanding distribution partner to support future deployment of Co-Dx™ PCR Pro® and expanding menu of molecular diagnostics products across a key Latin American market SALT LAKE CITY, June 11, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnosti...
06-11 21:05
Co-Diagnostics Advances Dual Ebola PCR Testing Program To Enhance Outbreak Detection And Surveillance In Africa
Dual-assay strategy designed to support outbreak response and surveillance efforts in affected regionsPotential blood-based Ebola assay would represent an important expansion of Co-Dx™ PCR point-of-care platform
06-02 21:09
Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara
Joint development strategy has been developed to address international deployment requirements if current outbreak continues or expands globally SALT LAKE CITY, May 26, 2026 /PRNewswire/ -- ...
05-26 21:00
Why JOYY Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Gainers: PHGE +97.3%, ARTL +74.8%, QTEX +52.4%, MNTX +34.4%, HLIT +28.3%, WOK +25%, CPSH +24.7%, CODX +22.7%, MDAI +22%. Losers: AKTX -25.2%, RYOJ -18.6%, DEVS -18.6%, AKAN -17%, ADTX -16.3%, LFS -15.6%
05-26 18:00
What's Going On With Co-Diagnostics Stock Wednesday?
Co-Diagnostics shares jump 28% following a $3.0M private placement and key progress on its Bundibugyo Ebola virus assay development.
05-20 23:24
Co-Diagnostics jumps 11%, raises $3M privately
Co-Diagnostics (CODX) announced a private placement agreement with institutional investors to sell 1.65M shares of common stock, or pre-funded warrants in lieu of shares, along with warrants to purcha...
05-20 14:30
U.S. CDC Says Will Enhance Screening And Monitoring Of Travelers Arriving From Areas Affected By Ebola Outbreaks; Will Coordinate With Airlines, Others To Manage Travelers Who May Have Already Been Exposed To Ebola; Will Enhance Contract Tracing, Hospital Readiness Nationwide
https://www.cdc.gov/ebola/situation-summary/index.html
05-18 23:25
电话会总结 ｜ Co-Diagnostics(CODX)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Co-Diagnostics业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **2026年第一季度财务表现：** - **总营收**：14.6万美元，同比增长192%（2025年同期为5万美元） - **毛利润**：亏损4.8万美元（2025年同期毛利润2.9万美元） - **净亏损**：910万美元，同比扩大21.3%（2025年同期净亏损750万美元） - **每股亏损**：4.06美元（完全稀释后），2025年同期为7.05美元 - **现金及现金等价物**：期末余额820万美元，较2025年底的1190万美元减少31.1% #
05-16 12:11
Co-Diagnostics Q1 2026 Earnings Call Transcript
Co-Diagnostics (NASDAQ:CODX) released first-quarter financial results and hoste...
05-15 05:26
